New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
10:01 EDTABBV, VRTX, TRLA, DLA, MLNX, PFE, VCLK, OPTR, FIO, SYRG, RBCN, FLY, GOOGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Delta Apparel (DLA) initiated with a Buy at Roth Capital... Fly Leasing (FLY) initiated with a Buy at Deutsche Bank... Google (GOOG) initiated with a Neutral at Sterne Agee... Optimer (OPTR) initiated with an Outperform at RW Baird... Trulia (TRLA) initiated with a Neutral at Goldman... ValueClick (VCLK) initiated with a Buy at Goldman... Vertex (VRTX) initiated with an Outperform at RW Baird... Rubicon (RBCN) coverage resumed with an Underweight at Piper Jaffray... Synergy Resources (SYRG) initiated with a Buy at Canaccord... Pfizer (PFE) reinstated with a Neutral at Credit Suisse... AbbVie (ABBV) initiated with a Neutral at Credit Suisse... Fusion-io (FIO) initiated with a Neutral at Janney Capital... Mellanox (MLNX) initiated with a Buy at Janney Capital.
News For GOOG;DLA;FLY;OPTR;TRLA;RBCN;VCLK;VRTX;SYRG;PFE;ABBV;FIO;MLNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
January 13, 2015
12:15 EDTABBVExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
09:36 EDTGOOGActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
07:36 EDTVRTXVertex price target raised to $146 from $125 at Piper Jaffray
Piper Jaffray raised its price target for Vertex Pharmaceuticals shares to $146 citing continued Kalydeco growth after the company issued 2015 guidance. Piper reiterates an Overweight rating on Vertex.
January 12, 2015
13:14 EDTGOOGAnalysts take opposite sides in regards to Google shares
Subscribe for More Information
12:45 EDTPFEActavis CEO says 'can't speculate on what Pfizer is going to do'
Subscribe for More Information
11:19 EDTGOOGGoogle set to provide real-time translation via Translate app, NY Times reports
Subscribe for More Information
10:00 EDTGOOGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:40 EDTGOOGGoogle no longer fixing older Android security flaws, WSJ reports
Subscribe for More Information
09:22 EDTPFE, GOOG23andMe announces collaboration with Pfizer
Google (GOOG)-backed 23andMe announced an agreement with Pfizer (PFE) that will provide Pfizer with access to 23andMe’s research platform, including services and Research Portal analysis of 23andMe’s genotyped population of over 800,000 individuals, of which more than 80 percent have consented to participate in research. 23andMe’s Research Portal enables qualified and approved scientists outside of 23andMe the opportunity to leverage the company’s unique research model while still protecting the privacy and security of 23andMe’s customers. As a part of the agreement, the companies will collaborate on certain genome-wide association studies, surveys, and clinical trial recruitment. One of these collaborations will be a longitudinal study to better understand the genetics of lupus. This study will entail enrollment and genotyping of 5,000 people into a new lupus research community, and include the integration of medical records, targeted bio-sampling along with genetic information for all participants. This announcement follows a collaboration between 23andMe and Pfizer to enroll 10,000 people with Inflammatory Bowel Disease in a research initiative designed to explore the genetic factors associated with the onset, progression, severity and response to treatments for IBD. Nearly 4,000 patients have been enrolled in the community since August 2014.
08:37 EDTPFEShire deal suggests most biotech companies in play, says JMP Securities
After Shire (SHPG) agreed to buy NPS Pharmaceuticals (NPSP), JMP Securities says the deal indicates that most biotech companies are in play, particularly those with worldwide rights to their products for well-defined patient populations. The firm expects investors to speculate all week about potential new targets in the space. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
08:21 EDTGOOGApple poised to gain market share, says JMP Securities
Subscribe for More Information
08:02 EDTGOOGGoogle shares undervalued, says Bernstein
Subscribe for More Information
08:01 EDTABBVAbbVie announces FDA approval of DUOPA enteral suspension
The FDA has approved AbbVie's DUOPA enteral suspension for the treatment of motor fluctuations for people with advanced Parkinson's disease. DUOPA is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine for 16 continuous hours via a procedurally-placed tube. DUOPA was approved by the FDA as an orphan drug, a designation granted to products intended for the treatment of rare diseases or conditions affecting fewer than 200,000 patients in the U.S.
07:38 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
07:17 EDTABBVJPMorgan to hold a conference
Subscribe for More Information
06:46 EDTGOOGGoogle downgraded to Neutral from Overweight at Atlantic Equities
Subscribe for More Information
January 11, 2015
21:04 EDTVRTXVertex expects Q4 Kalydeco revenue $460M
Subscribe for More Information
21:03 EDTVRTXVertex sees 2015 Kalydeco revenue $560M-$580M
Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. It said the increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor. Vertex's expected non-GAAP R&D and SG&A expenses exclude stock-based compensation expense and certain other expenses recorded in 2015. Vertex said entered 2015 with approximately $1.4B in cash, cash equivalents and marketable securities. Anticipated 2015 Kalydeco net revenues reflect: Use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; Use of KALYDECO in people in the United States with the R117H mutation following FDA approval in late 2014; The completion of reimbursement discussions for gating mutations in certain European countries; Use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015.
21:00 EDTVRTXVertex says NDA for combination of lumacaftor, ivacaftor accepted by FDA
Subscribe for More Information
20:57 EDTVRTXVertex says NDA for ivacaftor use in children accepted by FDA
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use